



# **What the Transfusion Scientist should know about Stem Cells**


Dr Claire Wiggins – BBTS September 2017

# What is a stem cell?

- 
- A thick, solid blue line that curves from the left side of the slide, dips down, and then curves back up towards the right side.
- Undifferentiated cell
  - Can divide and self renew for long periods
  - Differentiate into tissue or organ specific cells – specialised cells


# What is a Haemopoietic Stem Cell?

- 
- A thick blue wavy line that spans the width of the slide, separating the header from the main content.
- Haemopoietic progenitor cell, capable of reconstituting long term multi-lineage haemopoiesis
  - 1-3% cells in normal bone marrow, extremely rare in PB
  - Small lymphoid looking cells
  - Express CD34



# Bone Marrow Transplantation

*Blood and Transplant*

- 
- A thick blue wavy line that starts on the left, dips down, and then rises towards the right, separating the header from the main content.
- 1956 – BMT transplants in leukaemic mice
  - 1957 – First human allogeneic BMT transplants – 6 patients
  - 1959 – 1<sup>st</sup> European BMT on 5 nuclear workers whose own bone marrow damaged
  - 1968 – 1st BMT between siblings
  - 1970s – Renewed interest in autologous BMT
  - 1979 – 1<sup>st</sup> successful unrelated BMT
  - 1980s – Formation of donor panels

# Purpose of Stem Cell Transplantation

Treat a variety of blood related and metabolic disorders  
e.g. myeloma, lymphoma, leukaemia, SCID



Patient bone marrow cells eradicated through conditioning regimes



New population of HSC transplanted to repopulate the patients bone marrow. Also GvL effect

# Types of Stem Cell Transplant


## Autologous

- Stem cells collected from patient
- Cells 'rescue' patient after chemotherapy

## Allogeneic

- Stem cells collected from healthy donor
- HLA matched sibling
- Haploidentical family relative (partially matched)
- Unrelated volunteer
- Cryopreserved cord blood unit

# Sources of Haemopoietic Stem Cells

- 
- A thick, solid blue line that curves from the left side of the slide, dips down, and then curves back up towards the right side.
- Bone marrow
  - Mobilised peripheral blood
  - Cord blood



# Sources of Haemopoietic Stem Cells - Bone Marrow

- GA
- Marrow aspirated using needles/syringes
- Iliac crest
- 20ml/kg
- Approximately 3 weeks to be replaced




# Sources of Haemopoietic Stem Cells - Mobilised Peripheral Blood

- Recovery after chemotherapy
- Donors stimulated - Haematopoietic cytokines e.g. G-CSF
- Combined use of chemotherapy + G-CSF
- Plerixafor




# Mobilisation

*Blood and Transplant*



# CD34

- Stem Cell marker is CD34
- Correlation between blood and harvest
- PB CD34 expressed as cells/ $\mu$ l
- Harvest CD34 expressed as  $\times 10^6/\text{kg}$




# Cord

- Blood left on placenta and umbilical cord from delivery of baby
- Rich in stem cells
- Collected at registered hospitals




## Transplants by Cell Source



Source: National Marrow Donor Program FY 2012

# What we require prior to collection/processing

- 
- A thick blue wavy line that curves across the top of the slide, separating the header from the main content.
- Notice of intended dates for harvest
  - Request form
  - Consent form
  - Virology results/samples within 30 days of collection
  - Notice of time cells arriving on the day
  - Long line left on the collection bag

# Virology Screening – Minimum Requirement



*Blood and Transplant*

- 30 days prior to donation
- Anti-HIV 1 & 2
- Hepatitis B - HBsAg, Anti-HBc
- Anti-Hepatitis C Ab
- Anti HTLV 1 & 2 (if applicable)
- Syphilis
- Hep E from Sept 2017
- Additional tests (e.g. CMV, EBV, toxoplasma)
- Separate VAT for positive products
- Quarantine VAT for unscreened




# Transport of Products to Lab

- Product in sealed secondary bag in sealed thermally insulated validated transport box
- Traceability
- Labelled with contact details (to and from), inside and outside container
- Labelled with handling instructions
- Temperature – transport times <1 hour temperature range 2 – 37°C. Transport times 1 – 12 hours temperature range 2 – 24°C. Transport times >12 hours temperature range 2-8°C. Loggers sometimes used


# Receipt of Product in Lab

*Blood and Transplant*

- 
- A thick blue wavy line that spans the width of the slide, positioned below the header and above the list of bullet points.
- Inspect product for integrity, condition, labelling
  - Temperature of product on arrival
  - Sample taken from product for wcc, mnc, CD34 (stem cells), viability, bacteriology, CD3 (allogeneic)
  - Product may be stored overnight at 4°C in monitored temperature controlled fridge
  - Product may require diluting for o/n storage

# Processing/Preparation for Cryopreservation

- Some stem cell labs use cryodoc on bench using sterile dockers and heat sealer
- Some stem cell labs perform processing in cleanrooms



# Clean room Suite


- HEPA filtered, positive pressure

- Clean room – grade B


- Cabinets – grade A

- Over garments and undergarments

- Over garments sterile
- Prevent contamination
- Non-shedding synthetic fibres
- Private changing areas




# Cryopreservation

- 
- A thick blue wavy line that spans the width of the slide, separating the header from the main content.
- Dehydration and ice formation damage cells and tissues
  - Cryoprotectant required to protect the cells from freezing damage – DMSO most commonly used
  - Penetrating cryoprotectant
  - DMSO is cytotoxic, temperature dependant
  - Final concentration of 10% DMSO commonly used

# Cryopreservation of Stem Cells *Blood and Transplant*

- Equal volume of chilled 20% DMSO in plasma or HAS added slowly
- Dispensed into 2 or more Cryo-storage bags
- Also cryovials



# Cryopreservation of Stem Cells

- Controlled-rate freezer or passive freezing
- Cooling rate is important
- Controlled rate freezing programmes not standardised
- End point range -100 to -160°C
- Cells frozen at even rate throughout bag




# Storage

- Bags stored below  $-135^{\circ}\text{C}$   
(glass transition point)
- Cross contamination is minimised
  - Vapour-phase nitrogen
  - Double-wrapped
- Temperature is continuously monitored






# Quality control measures on products

- 
- A thick blue wavy line that curves across the top of the slide, separating the header from the main content.
- Total nucleated cell count (TNC)
  - Mononuclear cell count (MNC)
  - CD34 count (stem cells)
  - CD3 count (T cells for allogeneic products)
  - Viability
  - CFU assays
  - Bacteriology


# Flow Cytometry

- Viable CD34 positive cells enumerated, ISHAGE gating
- Viability measured using 7-aminoactinomycin D (7-AAD)
- Absolute number/ $\mu\text{l}$
- Calculated  $\text{CD34} \times 10^6/\text{kg}$
- Also viable CD3 positive cells measured for allogeneic products




# CFU Assay

- Cells plated in methyl cellulose
- Good indication of cell viability, functional assay
- Requires 14 day culture period
- Can be time consuming to read
- Number of colonies counted, expressed as CFU x  $10^4/\text{kg}$



# Bacteriology

- 
- A thick blue wavy line that starts on the left, dips down, and then rises towards the right, separating the header from the main content.
- Minimum requirements, post processing
  - Positive results, sensitivities performed
  - Reported to transplant clinician
  - Can still be transplanted, issued under concession
  - Antibiotic cover

# Autologous Transplant

## *Blood and Transplant*

- Request from transplant unit to issue cells for transplant
- Patient receives high dose chemotherapy
- Transported in cryoshipper, temperature monitored and alarmed
- Temperature  $< -150$  degC
- Accompanying paperwork for traceability




# Infusion of Cryopreserved Stem Cells


- Pre-medication (Piriton, Hydrocortisone) given to reduce risk of reaction to DMSO
- Bags thawed on the ward one at a time
  - Each bag infused within 20 minutes
- Infusion guidelines are  $<1\text{mL DMSO/Kg/day}$ 
  - Split infusion over 2 days



# Infusion Reactions

- 
- A thick blue wavy line that curves across the top of the slide, separating the header from the main content.
- Mild – Nausea, Vomiting, Abdominal cramps, Headache, Tachycardia, Shortness of breath, Shivering, Rigors, Aftertaste
  - Moderate/Severe – Reported to HTA on line and investigated, untoward occurrence, unintended response, fatal, life threatening, disabling, incapacitating or which results in, or prolongs, hospitalisation or morbidity

# Engraftment

- 
- A thick, solid blue line that curves across the top of the slide, starting from the left edge, dipping down in the middle, and then rising towards the right edge.
- Stem cells migrate to patients bone marrow
  - Requirement to monitor engraftment
  - Daily FBC
  - Neutrophil count  $>0.5$ , mean usually 11-13 days
  - Platelet count  $>20$ , mean usually 13-20 days
  - $>28$  days, delayed engraftment



# Allogeneic Transplants



## HLA Typing and Matching

- HLA (A, B, Cw, DR and DQ)
- Ideal is 10 out of 10 match.
- 30% of patients have a suitable fully matched related donor
- Unrelated donor, high resolution testing recommended
- ABO groups can be different
- CMV matching important - Transplant of a CMV positive graft into a negative recipient can cause a CMV infection - CMV negative graft into a positive recipient can cause CMV reactivation
- Age and gender of donor also taken into account

# Allogeneic Transplants

*Blood and Transplant*

- Patient has chemotherapy/radiotherapy
- Collection on hospital ward/clinic/operating theatre, via registry if unrelated
- Transported to the Stem Cell Lab
- Checks on receipt of product




# Allogeneic Transplants

*Blood and Transplant*


- Processing of product may be required
- Analysis of product, CD34, CD3, viability, bacteriology
- Issue of cells to hospital ward in cool box
- Traceability
- Infusion to patient
- Monitor engraftment, neutrophils  $>0.5$ , platelets  $>20$



# Donor Lymphocytes

- 
- A thick, solid blue line that curves from the left side of the slide, dips down in the middle, and then curves back up towards the right side.
- Cryopreservation of specific doses of T cells (CD3/kg) from donor
  - Treatment of relapse
  - Treatment of mixed chimerism
  - Risk of GvHD

# Blood Requirements

- 
- A thick blue wavy line that starts on the left, dips down, and then rises towards the right, separating the header from the main content.
- Irradiated blood products – any third party leucocytes could engraft and initiate an alloreactive response, TA-GvHD
  - CMV Negative – all CMV seronegative recipients, and seronegative donors, patients likely to proceed to transplant. CMV transmitted via leucocytes

# Blood Group Changes

## Major ABO incompatibility

- Presence in recipient's plasma of anti-A, anti-B or anti-A,B antibodies incompatible with donor red cells  
e.g. group A donor group O recipient
- *Risks:*
  - Acute haemolysis at time of HPC infusion
  - Delayed haemolysis due to production of antibodies by residual host lymphocytes  
Both above depend on vol. rbc's infused and titre of Ab (1:32 or greater)
  - Delayed red cell engraftment and pure red cell aplasia may occur

# Blood Group Changes


## Minor ABO incompatibility

- Presence of anti-A, anti-B, or anti-A,B antibodies in donor's plasma reactive with recipient's red cells  
e.g donor group O and recipient group A
  - *Risks:*
    - Acute haemolysis at time of infusion caused by anti-A or anti-B in plasma of donor product
    - Delayed haemolysis of recipient cells due to passenger lymphocytes syndrome
- Relates to volume of plasma and isoagglutinin titres of donor, and also body size of recipient

# Management of Group Changes

- **Pre-transplant:** samples from both donor and recipient for:
  - ABO and Rh D grouping and antibody screen
  - Anti-A and anti-B titres by indirect antiglobulin test (IAT) where indicated
  - Direct antiglobulin test (DAT)
- **Post transplant:**
  - Observe for group changes
  - Transient or permanent chimera



- 
- A thick blue wavy line that curves across the top of the slide, separating the header from the main content area.
- For major ABO mismatch use group O red cells products, irrespective of ABO group until recipient ABO antibodies are undetectable and the antiglobulin test is negative and platelets and plasma from donors of the recipients ABO type until recipient red cells no longer detected.
  - For minor ABO mismatch use red cells of the donor type i.e. group O throughout. Give platelets and plasma of recipient type until recipient-type red cells are no longer detected.
  - For major and minor ABO mismatch use group O red cells until recipient ABO antibodies are undetectable and the antiglobulin test is negative and then switch to donor type. For platelets and plasma use group AB until recipient red cells are undetectable.

Incompat- ibility	Donor Group	Recipient Group	Before Gp change RBs	Before Gp change Platelets	Before Gp change Plasma	After Gp change RBC ,Plt & Plasma Groups
Major	A	O	O	A	A	Rbc : A Platelets: A Plasma: A or AB
Minor	O	A	O	A	A	Rbc: O Plt: O FFP: O,A,B,AB

# Regulation - HTA

- April 2004 every tissue bank licensed
- Mandatory inspection started 2004-2005
- EU Cells and Tissue Directive
- HTA given authority over consent, procurement, testing, storage and distribution of cells



# Regulation - JACIE

- JACIE accreditation voluntary
- Clinical, collection and processing
- Standardisation of practice to international standards



A thick, solid blue line that curves across the top of the slide, starting from the left edge, dipping down, and then rising towards the right edge.

Any Questions?